Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers

被引:1
|
作者
Manyara, Anthony Muchai [1 ]
Ciani, Oriana [2 ]
Taylor, Rod S. [1 ,3 ]
机构
[1] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Berkeley Sq,99 Berkeley St, Glasgow G3 7HR, Lanark, Scotland
[2] SDA Bocconi Sch Management, Milan, Italy
[3] Univ Glasgow, Roberston Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
基金
英国医学研究理事会;
关键词
D O I
10.1002/trc2.12344
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Biomarkers and surrogate endpoints
    Aronson, JK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 491 - 494
  • [2] Evidence from Biomarkers and Surrogate Endpoints
    Feigin A.
    NeuroRX, 2004, 1 (3): : 323 - 330
  • [3] Comparing Biomarkers as Principal Surrogate Endpoints
    Huang, Ying
    Gilbert, Peter B.
    BIOMETRICS, 2011, 67 (04) : 1442 - 1451
  • [4] Biomarkers and surrogate endpoints in clinical trials
    Fleming, Thomas R.
    Powers, John H.
    STATISTICS IN MEDICINE, 2012, 31 (25) : 2973 - 2984
  • [5] Biomarkers of toxicity and surrogate endpoints for safety
    Sistare, FD
    Morrow, JD
    Olden, K
    BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, 2000, 1205 : 165 - 175
  • [6] Biomarkers and surrogate endpoints in kidney disease
    Erum A. Hartung
    Pediatric Nephrology, 2016, 31 : 381 - 391
  • [7] Biomarkers and surrogate endpoints in kidney disease
    Hartung, Erum A.
    PEDIATRIC NEPHROLOGY, 2016, 31 (03) : 381 - 391
  • [8] How can biomarkers become surrogate endpoints?
    Berns, B.
    Demolis, P.
    Scheulen, M. E.
    EJC SUPPLEMENTS, 2007, 5 (09): : 37 - 40
  • [9] Biomarkers and surrogate endpoints in glaucoma clinical trials
    Medeiros, Felipe A.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (05) : 599 - 603
  • [10] Imaging biomarkers as surrogate endpoints for drug development
    Richter, Wolf S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (Suppl 1) : S6 - S10